Samsung Bioepis Expands Sandoz Partnership with Five Next-Gen Biosimilar Candidates
Event summary
- Samsung Bioepis and Sandoz signed a global license, development, and commercialization agreement for up to five biosimilar candidates.
- SB36, referencing Entyvio (vedolizumab), is one of the key candidates under pre-clinical development.
- Samsung Bioepis will handle development, regulatory registration, and manufacturing, while Sandoz will manage global commercialization excluding China, Hong Kong, Taiwan, Macau, and South Korea.
- The agreement builds on their existing partnership for PYZCHIVA (ustekinumab) and EPYSQLI™ (eculizumab).
The big picture
This partnership expands the existing collaboration between Samsung Bioepis and Sandoz, reinforcing their commitment to improving access to biologic medicines. The deal underscores a broader industry trend toward strategic alliances in biosimilar development, aimed at reducing costs and increasing availability of life-changing treatments for patients with debilitating conditions.
What we're watching
- Pipeline Progress
- The pace at which Samsung Bioepis advances its biosimilar candidates through pre-clinical and clinical trials will determine the timeline for market entry.
- Regulatory Approvals
- How quickly regulatory bodies approve these biosimilars in key markets will impact their commercialization success.
- Market Competition
- Whether Samsung Bioepis and Sandoz can effectively compete against established brands like Entyvio (Takeda) and Soliris (Alexion).
Related topics